MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. cut its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 1.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 631,134 shares of the company's stock after selling 7,416 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 1.21% of PROCEPT BioRobotics worth $50,819,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors also recently bought and sold shares of PRCT. Raleigh Capital Management Inc. purchased a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at $32,000. Thematics Asset Management bought a new position in shares of PROCEPT BioRobotics in the fourth quarter worth about $46,000. Signaturefd LLC increased its stake in PROCEPT BioRobotics by 26.7% during the fourth quarter. Signaturefd LLC now owns 689 shares of the company's stock valued at $55,000 after acquiring an additional 145 shares during the period. IFP Advisors Inc acquired a new position in shares of PROCEPT BioRobotics in the 4th quarter worth approximately $58,000. Finally, Arcadia Investment Management Corp MI bought a new stake in shares of PROCEPT BioRobotics during the 4th quarter valued at $64,000. 89.46% of the stock is currently owned by hedge funds and other institutional investors.
PROCEPT BioRobotics Stock Performance
NASDAQ:PRCT traded up $0.57 during mid-day trading on Monday, hitting $58.64. The company's stock had a trading volume of 166,174 shares, compared to its average volume of 993,171. The business's fifty day moving average is $55.22 and its two-hundred day moving average is $71.77. PROCEPT BioRobotics Co. has a 1 year low of $47.04 and a 1 year high of $103.81. The stock has a market cap of $3.24 billion, a price-to-earnings ratio of -30.07 and a beta of 1.10. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07.
PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.04. The firm had revenue of $69.16 million for the quarter, compared to the consensus estimate of $65.39 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The company's revenue for the quarter was up 55.5% on a year-over-year basis. During the same period last year, the firm posted ($0.51) earnings per share. Analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.
Insider Activity
In other news, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the sale, the chief financial officer now owns 107,991 shares in the company, valued at approximately $6,161,966.46. This trade represents a 0.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Reza Zadno sold 5,475 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the completion of the sale, the chief executive officer now owns 173,070 shares of the company's stock, valued at $9,875,374.20. This trade represents a 3.07% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,455 shares of company stock worth $368,322. Corporate insiders own 6.60% of the company's stock.
Analyst Ratings Changes
A number of equities analysts recently commented on PRCT shares. Morgan Stanley reduced their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Truist Financial cut their price target on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a report on Friday, April 11th. Finally, Bank of America lowered their price objective on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating for the company in a research note on Friday, April 25th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $90.00.
View Our Latest Stock Analysis on PROCEPT BioRobotics
About PROCEPT BioRobotics
(
Free Report)
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
See Also
Before you consider PROCEPT BioRobotics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.
While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
